UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 9, 2019
ARDELYX, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36485 |
|
26-1303944 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
34175 Ardenwood Blvd., Suite 200
Fremont, CA 94555
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (510) 745-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, par value $0.0001 |
|
ARDX |
|
The Nasdaq Global Market |
Item 2.02 Results of Operations and Financial Condition.
On August 9, 2019, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished under this Item 2.02 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
Description |
|
99.1 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: August 9, 2019 |
|
|
|
ARDELYX, INC. |
||
|
|
|
|
|
By: |
|
/s/ Mark Kaufmann |
|
|
|
|
|
|
|
Mark Kaufmann |
|
|
|
|
|
|
|
Chief Financial Officer |
Exhibit 99.1
Ardelyx Reports Second Quarter 2019 Financial Results and
Recent Business Highlights
AMPLIFY clinical trial to read out 3Q19
PHREEDOM clinical trial to read out 4Q19
FREMONT, Calif., August 9, 2019 -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2019.
“We are excited for a catalyst-rich second half of 2019 with planned completion of the final stages of development for tenapanor before we seek approval for its use in treating hyperphosphatemia in end-stage renal disease patients on dialysis,” said Mike Raab, president and chief executive officer of Ardelyx. “There continues to be a high unmet need for novel hyperphosphatemia treatments to help ESRD patients achieve phosphorus goals. If positive, the results from our ongoing second Phase 3 clinical trial, PHREEDOM, investigating tenapanor as monotherapy, will allow us to file our NDA next year. If approved, tenapanor will provide patients and health care providers with a novel, first-in-class and much more patient-friendly approach to managing phosphorus levels in dialysis patients. We look forward to announcing results for PHREEDOM in the fourth quarter of this year, and announcing results for AMPLIFY, our ongoing Phase 3 clinical trial evaluating tenapanor’s use in combination with phosphate binders in the third quarter of this year.”
Remaining Expected 2019 Milestones
|
· |
Results from the PHREEDOM clinical trial, the company’s second Phase 3 clinical trial evaluating tenapanor as a monotherapy treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis, are currently expected to be announced in the fourth quarter of 2019. |
|
· |
Results from the AMPLIFY clinical trial, the company’s Phase 3 clinical trial evaluating tenapanor’s efficacy in combination with phosphate binders, are currently expected to be announced in the third quarter of 2019. |
|
· |
The company’s New Drug Application for U.S. marketing authorization of tenapanor for patients with IBS-C has a target action date under the Prescription Drug User Fee Act (PDUFA) of September 12, 2019. |
Second Quarter 2019 Financial Results
|
· |
Cash Position: As of June 30, 2019, Ardelyx had total capital resources including cash, cash equivalents and short-term investments of $123.9 million compared to total capital resources including cash, cash equivalents and short-term investments of $168.1 million as of December 31, 2018. |
|
· |
G&A Expenses: General and administrative expenses were $5.4 million for the three months ended June 30, 2019, a decrease of $0.7 million, or 12 percent, compared to $6.1 million for the three months ended June 30, 2018. The decrease was primarily related to a decrease in professional services and a reduction in stock-based compensation costs partially offset by an increase in headcount and related personnel costs. |
|
· |
Net Loss: Net loss for the three months ended June 30, 2019 was $25.5 million, or $0.41 per share, compared to a net loss of $22.3 million, or $0.42 per share, for the three months ended June 30, 2018. |
About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines. Ardelyx’s cardiorenal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease (ESRD) who are on dialysis, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and submitted a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, for the treatment of patients with IBS-C which has been granted a target action date under the Prescription Drug User Fee Act (PDUFA) of September 12, 2019. To efficiently bring its treatments to market, Ardelyx is pursuing strategic collaborations for tenapanor for IBS-C and hyperphosphatemia in certain territories. Ardelyx has established agreements with Kyowa Kirin (formerly known as Kyowa Hakko Kirin) in Japan, Fosun Pharma in China and Knight Therapeutics in Canada. For more information, please visit http://www.ardelyx.com and connect with us on Twitter @Ardelyx.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for Ardelyx’s product candidates in treating the diseases and conditions for which they are being developed, the potential for the use of tenapanor as monotherapy and in combination with phosphate binders for the treatment of hyperphosphatemia, Ardelyx’s expected timing for receipt and announcement of data from its ongoing Phase 3 clinical trials of tenapanor for the treatment of hyperphosphatemia in ESRD patients, and Ardelyx’s expected timing for filing of its NDA for tenapanor for hyperphosphatemia. Such forward-looking statements involve substantial risks and uncertainties that could cause the development of Ardelyx’s product candidates or Ardelyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process, including the regulatory approval process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s business in general, please refer to Ardelyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2019, and its future current and periodic reports to be filed with the Securities and Exchange Commission.
Investor and Media Contact:
Kimia Keshtbod
510-745-1751
kkeshtbod@ardelyx.com
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Alex Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Ardelyx, Inc.
Condensed Balance Sheets
(In thousands)
|
|
|
June 30, |
|
December 31, |
||
|
|
|
(Unaudited) |
|
(1) |
||
|
Assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
89,626 |
|
$ |
78,768 |
|
Short-term investments |
34,315 |
89,321 |
||||
|
Accounts receivable |
|
|
17 |
|
|
85 |
|
Unbilled license revenue |
|
|
— |
|
|
5,000 |
|
Property and equipment, net |
|
|
4,469 |
|
|
5,611 |
|
Right-of-use assets |
|
|
4,919 |
|
|
— |
|
Prepaid and other assets |
|
|
4,634 |
|
|
4,547 |
|
Total assets |
|
$ |
137,980 |
|
$ |
183,332 |
|
|
|
|
|
|
|
|
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
|
Accounts payable and other current liabilities |
|
$ |
14,015 |
|
$ |
16,728 |
|
Uncharged license fees |
|
|
— |
|
|
1,000 |
|
Current portion of operating lease liability |
|
|
2,318 |
|
|
— |
|
Operating lease liability, net of current portion |
|
|
3,433 |
|
|
— |
|
Loan payable, long term |
|
|
49,597 |
|
|
49,209 |
|
Other long-term liabilities |
|
|
— |
|
|
582 |
|
Stockholders’ equity |
|
|
68,617 |
|
|
115,813 |
|
Total liabilities and stockholders’ equity |
|
$ |
137,980 |
|
$ |
183,332 |
(1) Derived from the audited consolidated financial statements included on Form 10-K for the year ended December 31, 2018.
Ardelyx, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
||||||||
|
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
|
||||
|
|
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
||||
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing revenue |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
2,320 |
|
|
Other revenue |
|
|
18 |
|
|
30 |
|
|
18 |
|
|
30 |
|
|
Total revenues |
|
|
18 |
|
|
30 |
|
|
18 |
|
|
2,350 |
|
|
Cost of revenue |
|
|
— |
|
|
— |
|
|
— |
|
|
464 |
|
|
Gross Profit |
|
|
18 |
|
|
30 |
|
|
18 |
|
|
1,886 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
19,475 |
|
$ |
16,046 |
|
$ |
39,856 |
|
$ |
29,396 |
|
|
General and administrative |
|
|
5,371 |
|
|
6,138 |
|
|
10,488 |
|
|
12,329 |
|
|
Total operating expenses |
|
|
24,846 |
|
|
22,184 |
|
|
50,344 |
|
|
41,725 |
|
|
Loss from operations |
|
|
(24,828) |
|
|
(22,154) |
|
|
(50,326) |
|
|
(39,839) |
|
|
Other (expense) income |
|
|
(639) |
|
|
(135) |
|
|
(1,283) |
|
|
535 |
|
|
Provision for income taxes |
|
|
— |
|
|
(2) |
|
|
(2) |
|
|
(6) |
|
|
Net loss |
|
$ |
(25,467) |
|
$ |
(22,291) |
|
$ |
(51,611) |
|
$ |
(39,310) |
|
|
Net loss per common share, basic & diluted |
|
$ |
(0.41) |
|
$ |
(0.42) |
|
$ |
(0.82) |
|
$ |
(0.78) |
|
|
Shares used in computing net loss per share, basic and diluted |
|
|
62,651,863 |
|
|
52,824,483 |
|
|
62,599,371 |
|
|
50,206,470 |
|
####